AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20686919 — intervention group
Group type: COMPARATOR
Intervention: Comparison of all groups (I, II, III)
Number of subjects: 240
Study 18706905 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg/day transdermal estradiol
Number of subjects: 34
Study 18706905 — intervention group
Group type: COMPARATOR
Intervention: Transdermal placebo
Number of subjects: 34
Study 16624680 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol XL
Number of subjects: 13
Study 16624680 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol IR
Number of subjects: 13
Study 14615000 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program
Number of subjects: 153
Study 14615000 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 153
Study 10762502 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with RLS and PLMs
Number of subjects: 10
Study 10762502 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 10
Study 8968303 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 30 mg
Number of subjects: 114
Study 8968303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 8968303 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg
Number of subjects: 114
Study 1359846 — intervention group
Group type: EXPERIMENTAL
Intervention: 500-mg daily dose of zidovudine
Number of subjects: 1567
Study 1359846 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500-mg daily dose of zidovudine
Number of subjects: 1567
Study 1359846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1567
Study 1359846 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (both doses)
Number of subjects: 1567
Study 3925770 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciba transdermal nitroglycerin placebo patch
Number of subjects: 80
Study 3925770 — intervention group
Group type: COMPARATOR
Intervention: Transdermal patches (Ciba, Key, Searle)
Number of subjects: 80
Study 30623228 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (40 mg daily)
Number of subjects: 32
Study 30623228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 29733836 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 68
Study 29733836 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 68
Study 27404184 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation only
Number of subjects: 801
Study 27404184 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation plus financial incentives
Number of subjects: 801
Study 27404184 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 801
Study 24668103 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based alcohol screening and brief intervention (10 minutes of assessment and feedback)
Number of subjects: 3422
Study 24668103 — intervention group
Group type: COMPARATOR
Intervention: Control group (screening alone)
Number of subjects: 3422
Study 22785499 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell therapy group (n = 7; CABG and injection of bone marrow mononuclear cells (BMNCs) within MI areas)
Number of subjects: 14
Study 22785499 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 7; CABG alone)
Number of subjects: 14
Study 22785499 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell therapy group (n = 7)
Number of subjects: 14
Study 19959322 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin Choice decision aid
Number of subjects: 150
Study 19959322 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care visit without Statin Choice tool
Number of subjects: 150
Study 17693444 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day for 8 weeks
Number of subjects: 64
Study 15809394 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol hand sanitizer
Number of subjects: 2932
Study 15809394 — intervention group
Group type: COMPARATOR
Intervention: Traditional antiseptic handwash
Number of subjects: 2932
Study 12749424 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (s.c.) injection of 10,000 IU of hCG
Number of subjects: 40
Study 12749424 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (i.m.) injection of 10,000 IU of hCG
Number of subjects: 40
Study 10707441 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-priming
Number of subjects: 0
Study 10707441 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-alcohol priming
Number of subjects: 0
Study 10707441 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 8706443 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms of misoprostol administered vaginally every 12 hours, up to four times
Number of subjects: 234
Study 8706443 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms of misoprostol administered vaginally every 12 hours, up to four times
Number of subjects: 234
Study 1921255 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation (120 mmol potassium per day with 50% citrate and 50% bicarbonate)
Number of subjects: 12
Study 1921255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6810736 — intervention group
Group type: EXPERIMENTAL
Intervention: Merck 20‐micrograms hepatitis B virus (HBV) vaccine
Number of subjects: 1402
Study 6810736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1402
Study 30362649 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic machine perfusion (NMP)
Number of subjects: 20
Study 30362649 — intervention group
Group type: COMPARATOR
Intervention: Cold storage (CS)
Number of subjects: 20
Study 28657799 — intervention group
Group type: COMPARATOR
Intervention: Traditional IPC (4×5-min legs)
Number of subjects: 12
Study 28657799 — intervention group
Group type: COMPARATOR
Intervention: Unilateral IPC (4×5-min legs)
Number of subjects: 12
Study 28657799 — intervention group
Group type: COMPARATOR
Intervention: Remote IPC
Number of subjects: 12
Study 28657799 — intervention group
Group type: COMPARATOR
Intervention: 8×5-min IPC
Number of subjects: 12
Study 27071072 — intervention group
Group type: EXPERIMENTAL
Intervention: Hotspot-targeted interventions (larviciding, distribution of long-lasting insecticide-treated nets, indoor residual spraying, focal mass drug administration)
Number of subjects: 2042
Study 27071072 — intervention group
Group type: COMPARATOR
Intervention: Control group (malaria control following Kenyan national policy)
Number of subjects: 2042
Study 27071072 — intervention group
Group type: EXPERIMENTAL
Intervention: Hotspot-targeted interventions
Number of subjects: 2042
Study 24452658 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic only
Number of subjects: 120
Study 24452658 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic mixed with betamethasone
Number of subjects: 120
Study 22876835 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal therapeutic system (Bup‐TTS) 17.5 μg/h
Number of subjects: 45
Study 22876835 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal therapeutic system (Bup‐TTS) 35 μg/h
Number of subjects: 45
Study 22876835 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal therapeutic system (Bup‐TTS) 52.5 μg/h
Number of subjects: 45
Study 22876835 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal therapeutic system (Bup‐TTS)
Number of subjects: 45
Study 21133003 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection and pneumatic dilation (BT+PD)
Number of subjects: 34
Study 21133003 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic dilation (PD)
Number of subjects: 34
Study 17715139 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 0.1 mg kg(‐1)
Number of subjects: 557
Study 17715139 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.5 mg kg(‐1)
Number of subjects: 557
Study 15253175 — intervention group
Group type: EXPERIMENTAL
Intervention: Support received during diagnosis and treatment
Number of subjects: 544
Study 15253175 — intervention group
Group type: EXPERIMENTAL
Intervention: Support received by families of women with breast cancer
Number of subjects: 544
Study 15253175 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary sources of support
Number of subjects: 544
Study 11684527 — intervention group
Group type: EXPERIMENTAL
Intervention: CP‐DC diet (22 g cocoa powder and 16 g dark chocolate)
Number of subjects: 23
Study 11684527 — intervention group
Group type: COMPARATOR
Intervention: AAD (average American diet)
Number of subjects: 23
Study 9856424 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen syrup
Number of subjects: 230
Study 9856424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 7926968 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (either alone or associated with alpha-interferon)
Number of subjects: 21
Study 7926968 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-interferon
Number of subjects: 21
Study 7926968 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-interferon + corticosteroids
Number of subjects: 21
Study 7926968 — intervention group
Group type: COMPARATOR
Intervention: Untreated subjects
Number of subjects: 21
Study 7926968 — intervention group
Group type: EXPERIMENTAL
Intervention: Phorbol myristate acetate (PMA) treatment
Number of subjects: 21
Study 2478048 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (5 mg im)
Number of subjects: 150
Study 2478048 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (100 micrograms iv)
Number of subjects: 150
Study 2478048 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone (1 mg iv)
Number of subjects: 150
Study 2478048 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 150
Study 772660 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoxsuprine hydrochloride (Duvadilan Retard)
Number of subjects: 0
Study 772660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31388937 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative biopsy showing DCIS with palpable lump
Number of subjects: 606
Study 31388937 — intervention group
Group type: COMPARATOR
Intervention: Preoperative biopsy showing DCIS without palpable lump
Number of subjects: 606
Study 31388937 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative biopsy showing DCIS with necrosis
Number of subjects: 606
Study 31388937 — intervention group
Group type: COMPARATOR
Intervention: Preoperative biopsy showing DCIS without necrosis
Number of subjects: 606
Study 31388937 — intervention group
Group type: EXPERIMENTAL
Intervention: 14G core-needle biopsy
Number of subjects: 606
Study 31388937 — intervention group
Group type: COMPARATOR
Intervention: 9G vacuum-assisted biopsy
Number of subjects: 606
Study 28059869 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal supra‐inguinal fascia iliaca compartment block with 40‐mL ropivacaine 0.5%
Number of subjects: 88
Study 28059869 — intervention group
Group type: COMPARATOR
Intervention: Control group (no block)
Number of subjects: 88
Study 26083360 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent cycles of remote ischemic preconditioning (IPC)
Number of subjects: 40
Study 26083360 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (Control)
Number of subjects: 40
Study 23689115 — intervention group
Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation (PRP) plus intravitreal bevacizumab (IVB) injections
Number of subjects: 42
Study 23689115 — intervention group
Group type: COMPARATOR
Intervention: Panretinal photocoagulation (PRP) alone
Number of subjects: 42
Study 21640613 — intervention group
Group type: EXPERIMENTAL
Intervention: ND-ind group (n = 30)
Number of subjects: 120
Study 21640613 — intervention group
Group type: COMPARATOR
Intervention: ND >110 group (n = 30)
Number of subjects: 120
Study 21640613 — intervention group
Group type: EXPERIMENTAL
Intervention: DM-30 group (n = 30)
Number of subjects: 120
Study 21640613 — intervention group
Group type: COMPARATOR
Intervention: DM-60 group (n = 30)
Number of subjects: 120
Study 21640613 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results for diabetics and nondiabetics
Number of subjects: 120
Study 19784815 — intervention group
Group type: COMPARATOR
Intervention: Short balloon inflation (deflated immediately after imaging at 14 atm)
Number of subjects: 92
Study 19784815 — intervention group
Group type: EXPERIMENTAL
Intervention: Long balloon inflation (60 s at 14 atm)
Number of subjects: 92
Study 17019290 — intervention group
Group type: EXPERIMENTAL
Intervention: Masai Barefoot Technology (MBT) shoe
Number of subjects: 123
Study 17019290 — intervention group
Group type: COMPARATOR
Intervention: High-end walking shoe (control)
Number of subjects: 123
Study 15134316 — intervention group
Group type: EXPERIMENTAL
Intervention: Not On Tobacco (N‐O‐T) program
Number of subjects: 258
Study 15134316 — intervention group
Group type: COMPARATOR
Intervention: 15‐min single‐dose brief intervention
Number of subjects: 258
Study 11375808 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (50 micro/kg) administered through the bypass pump 10 min before aortic cross-clamping
Number of subjects: 20
Study 11375808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9404430 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy (specifics not provided)
Number of subjects: 2250
Study 9404430 — intervention group
Group type: COMPARATOR
Intervention: Previously treated patients or patients with cardiovascular complications
Number of subjects: 2250
Study 8495453 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac-K 50 mg
Number of subjects: 72
Study 8495453 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac-K 100 mg
Number of subjects: 72
Study 8495453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 3103663 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil plus etomidate
Number of subjects: 44
Study 3103663 — intervention group
Group type: COMPARATOR
Intervention: fentanyl plus thiopentone
Number of subjects: 44
Study 30844477 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger supplementation (1500 mg daily for 12 weeks)
Number of subjects: 70
Study 30844477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 29085257 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 373
Study 29085257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373
Study 29085257 — intervention group
Group type: EXPERIMENTAL
Intervention: sANSWERS
Number of subjects: 373
Study 29085257 — intervention group
Group type: EXPERIMENTAL
Intervention: GPA, ANSWERS, PoPLR
Number of subjects: 373
Study 25313450 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Weight (HW) intervention - 4 telephone coaching sessions on weight and physical activity
Number of subjects: 313
Study 25313450 — intervention group
Group type: COMPARATOR
Intervention: Physical Activity (PA) intervention - 2 telephone coaching sessions on physical activity
Number of subjects: 313
Study 23137828 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (60 min run at 72% of VO(2)max)
Number of subjects: 10
Study 23137828 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 10
Study 20962652 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia with sevoflurane (group S)
Number of subjects: 60
Study 20962652 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia with propofol (group P)
Number of subjects: 60
Study 20962652 — intervention group
Group type: COMPARATOR
Intervention: Epidural anaesthesia (group E)
Number of subjects: 60
Study 19085787 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombophilic defects present in NAION patients
Number of subjects: 76
Study 19085787 — intervention group
Group type: COMPARATOR
Intervention: Thrombophilic defects present in controls
Number of subjects: 76
Study 19085787 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of factor VIII
Number of subjects: 76
Study 19085787 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of lipoprotein (a)
Number of subjects: 76
Study 19085787 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without cardiovascular risk factors
Number of subjects: 76
Study 16583424 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice weekly
Number of subjects: 0
Study 16583424 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 0
Study 16583424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15253720 — intervention group
Group type: EXPERIMENTAL
Intervention: Disector/Fractionator method
Number of subjects: 0
Study 15253720 — intervention group
Group type: COMPARATOR
Intervention: Weibel-Gomez method
Number of subjects: 0
Study 11736876 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artesunate (4 mg kg(‐1))
Number of subjects: 14
Study 11736876 — intervention group
Group type: COMPARATOR
Intervention: Oral artemether (4 mg kg(‐1))
Number of subjects: 14
Study 11736876 — intervention group
Group type: COMPARATOR
Intervention: Oral artemether (first day of treatment)
Number of subjects: 14
Study 11736876 — intervention group
Group type: COMPARATOR
Intervention: Oral artemether (second day of treatment)
Number of subjects: 14
Study 11736876 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo parasite clearance and time above the in vitro IC90 for both drugs
Number of subjects: 14
Study 9245924 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (0.1 ng/kg subcutaneously)
Number of subjects: 20
Study 9245924 — intervention group
Group type: COMPARATOR
Intervention: Octreotide (0.01 microgram, 0.1 microgram, or 1 microgram subcutaneously thrice a day for three days)
Number of subjects: 20
Study 9245924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8328291 — intervention group
Group type: EXPERIMENTAL
Intervention: Random practice schedule with longer summary KR (KR10)
Number of subjects: 72
Study 8328291 — intervention group
Group type: COMPARATOR
Intervention: Blocked practice schedule with KR after each practice trial
Number of subjects: 72
Study 8328291 — intervention group
Group type: COMPARATOR
Intervention: Blocked practice schedule with 100% KR
Number of subjects: 72
Study 3511660 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 360 mg/day
Number of subjects: 77
Study 3511660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 29383063 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5× speed video playback for artifacts quiz
Number of subjects: 54
Study 29383063 — intervention group
Group type: COMPARATOR
Intervention: 1.0× speed video playback for artifacts quiz (Control)
Number of subjects: 54
Study 29383063 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5× speed video playback for transducers assessment
Number of subjects: 54
Study 29383063 — intervention group
Group type: COMPARATOR
Intervention: 1.0× speed video playback for transducers assessment (Control)
Number of subjects: 54
Study 28598116 — intervention group
Group type: EXPERIMENTAL
Intervention: LE+CC
Number of subjects: 209
Study 28598116 — intervention group
Group type: EXPERIMENTAL
Intervention: LE+HMG
Number of subjects: 209
Study 28598116 — intervention group
Group type: EXPERIMENTAL
Intervention: CC+HMG
Number of subjects: 209
Study 28598116 — intervention group
Group type: EXPERIMENTAL
Intervention: LE+CC+HMG
Number of subjects: 209
Study 25057119 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based patient narratives intervention; website usage: 46.1% (119/258).
Number of subjects: 571
Study 25057119 — intervention group
Group type: EXPERIMENTAL
Intervention: Website usage (at least 3 times).
Number of subjects: 571
Study 25057119 — intervention group
Group type: COMPARATOR
Intervention: Control group (no website usage).
Number of subjects: 571
Study 22836479 — intervention group
Group type: EXPERIMENTAL
Intervention: High Atrial Pacing (HAP; basic rate at 70 bpm, dual sensor with optimized slope, overdrive pacing)
Number of subjects: 79
Study 22836479 — intervention group
Group type: COMPARATOR
Intervention: Low Atrial Pacing (LAP; basic rate at 60 bpm, dual sensor with minimal slope)
Number of subjects: 79
Study 22836479 — intervention group
Group type: EXPERIMENTAL
Intervention: High Atrial Pacing (HAP)
Number of subjects: 79
Study 22836479 — intervention group
Group type: COMPARATOR
Intervention: Low Atrial Pacing (LAP)
Number of subjects: 79
Study 22836479 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HAP and LAP
Number of subjects: 79
Study 21188918 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine needle aspirational cytology (FNAC)
Number of subjects: 46
Study 21188918 — intervention group
Group type: COMPARATOR
Intervention: Open surgical biopsy
Number of subjects: 46
Study 18667086 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4000IU 25(OH)D3 per day)
Number of subjects: 84
Study 18667086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 11464141 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (Group A)
Number of subjects: 106
Study 11464141 — intervention group
Group type: COMPARATOR
Intervention: Protease Inhibitor (Group B)
Number of subjects: 106
Study 9552778 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine + both (i.t. 10 mg bupivacaine + 50 microg neostigmine + 150 microg clonidine)
Number of subjects: 80
Study 9552778 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine (i.t. 10 mg bupivacaine)
Number of subjects: 80
Study 9552778 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine + neostigmine (i.t. 10 mg bupivacaine + 50 microg neostigmine)
Number of subjects: 80
Study 9552778 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine + clonidine (i.t. 10 mg bupivacaine + 150 microg clonidine)
Number of subjects: 80
Study 7868704 — intervention group
Group type: EXPERIMENTAL
Intervention: Siblings of children with cancer after diagnosis
Number of subjects: 254
Study 7868704 — intervention group
Group type: COMPARATOR
Intervention: Matched controls from the Child Health Supplement of the National Health Interview Survey (CHS88)
Number of subjects: 254
Study 3421598 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse Prevention treatment
Number of subjects: 44
Study 3421598 — intervention group
Group type: COMPARATOR
Intervention: No-treatment group (control)
Number of subjects: 44